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Xeroderma pigmentosum (XP) is a potentially life-
threatening disease, in which avoidance of ultraviolet 
light (UV) is necessary (1). In cases in which preventive 
measures fail, treatment of skin neoplasms is challenging 
and requires a multidisciplinary approach. Consecutive 
surgical interventions may result in devastating cuta-
neous defects, which determine the quality of life (QoL) 
of the patients. Electrochemotherapy (ECT) is a novel 
therapeutic option that ablates tumours with electrical 
current and simultaneously administered anticancer 
drugs (2). In various cutaneous and subcutaneous neo-
plasia, this method has been proven to provide long-
lasting local control with minimal side-effects and good 
cosmetic results (3, 4).
CASE REPORT
An 11-year-old girl with XP was referred to our dermato-oncology 
centre with advanced non-melanoma skin cancers (NMSCs) on 
her face. Xerosis, skin atrophy, freckling and numerous scars from 
previous surgical interventions were noted on the skin surface. 
Unfortunately, her photoprotection in the past had been inadequate. 
Numerous plaques, nodules and ulcers 5–10 mm in diameter had 
presented, with the clinical appearance of basal cell carcinomas 
(BCCs). A locally advanced squamous cell carcinoma (SCC) had 
destroyed the surrounding tissues around the left nostril. On the 
left thigh, a tumour resembling keratoacanthoma (KA) 15 mm 
in diameter with a central keratotic plug was growing rapidly. 
Ophthalmological examination revealed photophobia and ectro-
pion. Neurological examination, intelligence quotient (IQ) testing, 
radiological imaging and laboratory results were without signifi-
cant pathological findings. Genetic investigations were performed 
on the genomic deoxyribonucleic acid (DNA) isolated from a 
peripheral blood sample from the patient. Direct sequencing of 
the XPC gene revealed a recurrent disease-causing homozygous 
nonsense mutation (c.463C/T; p.Arg155X) in the third exon (5).
Since the SCC in her central facial region could not be resected 
without causing a devastating defect, our multidisciplinary tumour 
board considered other treatment options. Although there are no 
published data regarding ECT in XP-C or in childhood, we deci-
ded to explore this treatment modality in our case (6). Our patient 
did not have risk factors for pulmonary fibrosis, which we had 
to consider before the administration of bleomycin. Prior to the 
procedure we obtained approval from the local ethics committee, 
the dermato-oncology and the paediatric-oncology tumour board. 
The patient’s parents also gave their written informed consent. 
ECT sessions were carried out in our department in accordance 
with the European Standard Operating Procedure guidelines with 
the Cliniporator TM device (IGEA Ltd., Modena, Italy) (7). De-
pending on the size and clinical feature of the tumours, different 
types of electrodes were chosen. In case of nodules smaller than 
1.0 cm in diameter electrical pulses were delivered either using 
parallel arrays or, for exophytic lesions, plate electrodes. For larger 
nodules, hexagonal array needle electrodes were connected to the 
electroporation device. If required, a second run was delivered or 
the electrode was repositioned until complete tumour electropora-
tion was obtained. A safety margin of 3–5 mm was treated around 
every nodule. Electrical parameters were as follows: for type II 
electrodes, 8 electric pulses of 1,000 V/cm amplitude over distance 
ratio and 100 ms duration, delivered at 1 or 5,000 Hz repetition 
frequency and, for type III electrodes, 96 electric pulses (8 pulses 
per pair of needles) of 1,000 V/cm amplitude over distance ratio 
and 100 ms duration, delivered at 5,000 Hz repetition frequency. 
At each session, the patient received intravenous bleomycin (15 
mg/m2). Electrical pulses were delivered to the tumours during 
the pharmacokinetic peak (8–28 min following the administration 
of bleomycin). The ECT sessions were carried out under general 
anaesthesia, and the patient was monitored for the subsequent 
24 h. During the follow-up period, dermoscopy, confocal mi-
croscopy and histology were used to detect residual tumours and 
new lesions. Response to treatment was assessed according to the 
World Health Organization (WHO) criteria at least 4 months after 
intervention. Sessions were repeated at 2-monthly intervals until 
a complete response (CR) was achieved. 
The patient underwent 5 ECT sessions in one year. The mean 
number of treated tumours was 17 per session (11–25), the mean 
diameter was 0.85 cm (0.3–3.6 cm), and most of them (82%) were 
localized in the head and neck region. After 5 sessions of ECT, CR 
was achieved in 33 (97%) of the treated tumours (Fig. 1 and Fig. 
S11). Progressive disease (PD) was noticed in one lesion (3%), a 
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Fig. 1. Clinical course before and after therapy. (a) Squamous cell carcinoma and basal cell carcinomas before treatment, (b) 8 weeks after the first 
session of electrochemotherapy (ECT), (c) 2 weeks and (d) 15 months after the second session of ECT.
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rapidly growing KA-like lesion on the right hand, and appeared 
after the fourth ECT session. Following a biopsy from the lesion, 
our tumour board decided to refer the patient to a hand surgeon. 
Removal of the SCC was possible only with amputation of the 
fourth digit. None of the lesions showing CR relapsed during 
the follow-up period (4–15 months). Pain was not observed fol-
lowing the ECT sessions. We observed sore muscles, mild and 
transient erythema and oedema around the treated lesions. During 
the healing process, 2–3 weeks after ECT, central or complete 
necrosis developed in the treated tumours. Skin marks from the 
needle electrodes were visible for approximately one month. No 
systemic side-effects were observed, and the lung functional tests 
following the ECT sessions were normal. Due to her disease, our 
patient also had microstoma, ectropion and disfiguring scarring 
of the midface and upper lip. The patient had difficulty closing 
her eyelids and eating, with intubation also posing a challenge 
during general anaesthesia. Combined with ECT sessions, re-
constructive surgeries were performed, and the function of the 
eyelids and lips improved significantly. Residual tumours were 
not detected with a histological examination of the lesions, which, 
clinically, had a CR. 
DISCUSSION
Based on a literature review, this is the first report of the 
successful use of ECT both in childhood NSMC and in 
XP-C. 
In the XP-C group multifocal NMSCs may represent 
one of the main health problems and are often the major 
determinants of life expectancy in advanced cases. 
Multiple interventions and drugs are potentially 
available for the treatment of NMSC, but data in the 
literature with regard to their use in XP are limited or 
conflicting. Radiotherapy (RT) can be used for patients 
with XP; how ever, this is not recommended in the current 
guidelines and is debated in childhood (8). Surgery is the 
mainstay of therapy, but proper surgical management ful-
filling oncological and aesthetic criteria is often difficult. 
Removal of the continuously arising tumours can result 
in disfiguring scars and devastating cutaneous defects. 
ECT has proved to be safe and effective in the local 
tumour control of NMSCs (9, 10). The method is recom-
mended in carefully selected patients for difficult-to-
treat NMSCs, which do not respond to, or are no longer 
suitable for, surgery (11). CR can be achieved in most 
cases, with a single session of ECT. In cases with multiple 
tumours, the significant advantage of ECT compared with 
conventional surgery is, that numerous tumours can be 
treated at the same time and, while its effect on normal 
tissue is minimal, it leads to good cosmetic results.
The XPC polymorphisms (p.Lys939Gln, c.IVS11-
5C>A) associated bleomycin-induced chromosomal 
aberrations signify clinically important risk for patients 
with XP-C (12). Based on the sequencing results, our 
patient carries the wild-type genotypes (TT and CC) of 
the p.Lys939Gln and c.IVS11-5C>A polymorphisms, 
therefore the repeated administration of bleomycin may 
not cause chromosomal aberrations, although long-term 
follow-up is necessary.
Based on the available evidence and on our experience 
with Gorlin–Goltz syndrome (13), we explore here the 
use of ECT for the numerous NMSCs in an 11-year-old 
child with XP-C. ECT provided good local control of 
the locally advanced, unresectable SCC on her face 
and of the multiple BCCs with preservation of organ 
function and an acceptable aesthetic result. There was 
no post-procedure pain after  ECT, i.e. consistent with 
a previous report (14). Since numerous lesions can be 
treated during a single ECT session, the psychological 
burden of multiple surgeries can be reduced, which is 
especially important in childhood.
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